257 related articles for article (PubMed ID: 15070665)
1. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients.
Berentsen S; Ulvestad E; Gjertsen BT; Hjorth-Hansen H; Langholm R; Knutsen H; Ghanima W; Shammas FV; Tjønnfjord GE
Blood; 2004 Apr; 103(8):2925-8. PubMed ID: 15070665
[TBL] [Abstract][Full Text] [Related]
2. Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease.
Berentsen S; Tjønnfjord GE; Brudevold R; Gjertsen BT; Langholm R; Løkkevik E; Sørbø JH; Ulvestad E
Br J Haematol; 2001 Oct; 115(1):79-83. PubMed ID: 11722415
[TBL] [Abstract][Full Text] [Related]
3. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
4. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease.
Berentsen S; Randen U; Vågan AM; Hjorth-Hansen H; Vik A; Dalgaard J; Jacobsen EM; Thoresen AS; Beiske K; Tjønnfjord GE
Blood; 2010 Oct; 116(17):3180-4. PubMed ID: 20634373
[TBL] [Abstract][Full Text] [Related]
5. Beneficial effect of rituximab in combination with oral cyclophosphamide in primary chronic cold agglutinin disease.
Vassou A; Alymara V; Chaidos A; Bourantas KL
Int J Hematol; 2005 Jun; 81(5):421-3. PubMed ID: 16158824
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial.
Berentsen S; Randen U; Oksman M; Birgens H; Tvedt THA; Dalgaard J; Galteland E; Haukås E; Brudevold R; Sørbø JH; Næss IA; Malecka A; Tjønnfjord GE
Blood; 2017 Jul; 130(4):537-541. PubMed ID: 28533306
[TBL] [Abstract][Full Text] [Related]
7. Severe refractory autoimmune hemolytic anemia with five-year complete hematologic response to third course of treatment with rituximab: a case report.
Abadie K; Hege KM
J Med Case Rep; 2014 Jun; 8():175. PubMed ID: 24889270
[TBL] [Abstract][Full Text] [Related]
8. Mixed warm and cold autoimmune hemolytic anemia: complete recovery after 2 courses of rituximab treatment.
Morselli M; Luppi M; Potenza L; Tonelli S; Dini D; Leonardi G; Donelli A; Narni F; Torelli G
Blood; 2002 May; 99(9):3478-9. PubMed ID: 12001903
[No Abstract] [Full Text] [Related]
9. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients.
Schöllkopf C; Kjeldsen L; Bjerrum OW; Mourits-Andersen HT; Nielsen JL; Christensen BE; Jensen BA; Pedersen BB; Taaning EB; Klausen TW; Birgens H
Leuk Lymphoma; 2006 Feb; 47(2):253-60. PubMed ID: 16321854
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of cold agglutinin disease with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus.
Kotani T; Takeuchi T; Kawasaki Y; Hirano S; Tabushi Y; Kagitani M; Makino S; Hanafusa T
Lupus; 2006; 15(10):683-5. PubMed ID: 17120596
[TBL] [Abstract][Full Text] [Related]
11. [Rituximab in cold agglutinin disease].
Camou F; Viallard JF; Pellegrin JL
Rev Med Interne; 2003 Aug; 24(8):501-4. PubMed ID: 12888170
[TBL] [Abstract][Full Text] [Related]
12. [Cold agglutinin disease - no response to glucocorticoids and rituximab, what treatment is best for the 3rd line of therapy? Case report and review of the literature].
Adam Z; Pejchalová A; Chlupová G; Ríhová L; Pour L; Krejčí M; Cervinek L; Král Z; Mayer J
Vnitr Lek; 2013 Sep; 59(9):828-40. PubMed ID: 24073955
[TBL] [Abstract][Full Text] [Related]
13. Cold agglutinin-mediated autoimmune hemolytic anemia in Waldenström's macroglobulinemia.
Berentsen S
Clin Lymphoma Myeloma; 2009 Mar; 9(1):110-2. PubMed ID: 19362990
[TBL] [Abstract][Full Text] [Related]
14. [Delayed response to rituximab of cold agglutinin haemolytic disease].
Calvo-Villas JM; Cuesta Tovar J; Carreter de Granda E; Sicilia Guillén F
An Med Interna; 2006 May; 23(5):224-8. PubMed ID: 16817700
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children.
Zecca M; Nobili B; Ramenghi U; Perrotta S; Amendola G; Rosito P; Jankovic M; Pierani P; De Stefano P; Bonora MR; Locatelli F
Blood; 2003 May; 101(10):3857-61. PubMed ID: 12531800
[TBL] [Abstract][Full Text] [Related]
16. Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder.
Jourdan E; Topart D; Richard B; Jourdan J; Sotto A
Leuk Lymphoma; 2003 May; 44(5):889-90. PubMed ID: 12802933
[TBL] [Abstract][Full Text] [Related]
17. Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy.
Berentsen S; Beiske K; Tjønnfjord GE
Hematology; 2007 Oct; 12(5):361-70. PubMed ID: 17891600
[TBL] [Abstract][Full Text] [Related]
18. Rituximab-containing therapy for cold agglutinin disease: a retrospective study of 16 patients.
Jia MN; Qiu Y; Wu YY; Cai H; Zhou DB; Cao XX; Li J
Sci Rep; 2020 Jul; 10(1):12694. PubMed ID: 32728060
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia.
Zecca M; De Stefano P; Nobili B; Locatelli F
Blood; 2001 Jun; 97(12):3995-7. PubMed ID: 11389047
[TBL] [Abstract][Full Text] [Related]
20. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia.
Peñalver FJ; Alvarez-Larrán A; Díez-Martin JL; Gallur L; Jarque I; Caballero D; Díaz-Mediavilla J; Bustelos R; Fernández-Aceñero MJ; Cabrera JR;
Ann Hematol; 2010 Nov; 89(11):1073-80. PubMed ID: 20526716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
